1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
Vaidya Sane Ayurved Laboratories Ltd.

Vaidya Sane Ayurved Laboratories Ltd.

MADHAVBAUG.NS
Vaidya Sane Ayurved Laboratories Ltd.IN flagNational Stock Exchange of India
- -
INR
- -
- -
- -
- -
(- -)

Recent

price

- -

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
FRC
59.44
71.56
49.72
172.26
94.33
94.46
85.44
Revenue per Share
0.47
-0.53
0.37
8
4.6
1.88
6.79
Basic EPS, GAAP
1.51
7.34
4.61
-37.57
-6.58
-11.8
2.05
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.25
0.25
- -
Dividend per Share
8.25
7.71
9.18
38.68
20.3
21.93
28.73
Book Value per Share
6.93
6.75
8.86
80.33
36.09
45.65
46.66
Tangible Book Value per Share
11
11
11
4
11
11
11
Basic Weighted Avg Shares
625
752
523
747
992
993
898
Sales/Revenue/Turnover
2.41
0.91
3.92
6.76
5.98
1.38
10.54
Operating Margin (%)
16
22
24
23
26
31
42
Depreciation Expense
5
-6
4
35
48
20
71
Net Income, GAAP
43.75
- -
13.81
26.95
24.87
30.52
27.73
Effective Tax Rate (%)
0.79
-0.74
0.75
4.64
4.87
1.99
7.94
Profit Margin (%)
-90
-102
-67
130
149
197
191
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
88
82
98
359
405
556
625
Total Equity
- -
- -
13.38
14.58
11.26
1.93
11.12
Return on Invested Capital (%)
- -
- -
5.28
25.37
25.3
9.32
25.56
Return on Capital (%)
- -
-6.64
4.41
26.25
25.36
8.92
26.79
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
69.77%
12.47%
Free Cash Flow
- -
-113.72%
-117.37%
Net Income, GAAP
- -
171.04%
260.34%
Sales/Revenue/Turnover
- -
7.15%
-9.55%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
993
2025
- -
- -
- -
- -
898
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.88
2025
- -
- -
- -
- -
6.79
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.25
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
BioCorRx Inc. (BICX)
ProstaLund AB (publ) (PLUN.ST)
Saint-Care Holding Corporation (2374.T)
IMAC Holdings, Inc. (IMACW)
Bumrungrad Hospital Public Company Limited (BUHPF)
Nobilis Health Corp. (NRTSF)
Business
Vaidya Sane Ayurved Laboratories Ltd (MADHAVBAUG.NS) operates a chain of clinics and hospitals under the Madhavbaug brand, specializing in non-invasive Ayurveda-based treatments for chronic cardiac and lifestyle conditions; core services include heart disease reversal, diabetes reversal, hypertension management, obesity management, knee pain relief, panchakarma therapies, diagnostics, diet counseling, and physiotherapy. The company manufactures and sells in-house Ayurvedic medicines and nutritional products, such as Repoz Tablets, Pure Tanupushti Oil, Carbi Tablets, Ayurvedic Herbal Laxsa, and Dolorex Tablets, through its clinics, franchises, and hospitals. Incorporated in 1999 and headquartered in Thane, Maharashtra, India, it serves patients across approximately 360 clinics in states including Maharashtra, Madhya Pradesh, Gujarat, Uttar Pradesh, Goa, Karnataka, Delhi, Punjab, Uttarakhand, West Bengal, and Chhattisgarh, complemented by three cardiac prevention and rehabilitation hospitals in Khopoli, Kondhali, and Visakhapatnam. In recent developments, the company completed the acquisition of Dynamic Remedies Private Limited and UV Ayurgen Pharma Private Limited in September 2023 for INR 50 million to bolster its product portfolio and manufacturing capabilities. It made Aaharshastra a wholly-owned subsidiary and entered a 70:30 profit-sharing memorandum of understanding (MoU) with a Malaysian partner in November 2025 to expand internationally. Vaidya Sane Ayurved Laboratories plans hospital expansions, including increased bed capacity at Khopoli, new facilities in Gujarat and North India, a state-of-the-art factory for enhanced production, cashless treatment empanelments with insurance providers and CGHS, and full NABH accreditation, alongside a preferential warrants issue of INR 102.48 crore to fund growth initiatives.